Sei Investments Co. Sells 49,577 Shares of DBV Technologies S.A. $DBVT

Sei Investments Co. cut its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 74.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,764 shares of the company’s stock after selling 49,577 shares during the period. Sei Investments Co.’s holdings in DBV Technologies were worth $350,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Allworth Financial LP acquired a new stake in DBV Technologies during the 4th quarter valued at approximately $32,000. Royal Bank of Canada bought a new stake in shares of DBV Technologies in the 4th quarter valued at $34,000. Truvestments Capital LLC boosted its stake in shares of DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of DBV Technologies in the 4th quarter valued at $115,000. Finally, Two Sigma Investments LP acquired a new stake in shares of DBV Technologies during the third quarter worth $167,000. 71.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on DBVT. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Weiss Ratings lowered DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Guggenheim reissued a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th. Finally, Citizens Jmp boosted their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $14.02 on Monday. The company has a fifty day moving average of $15.21 and a 200-day moving average of $18.70. The firm has a market capitalization of $881.58 million, a P/E ratio of -3.99 and a beta of -0.93. DBV Technologies S.A. has a twelve month low of $8.70 and a twelve month high of $26.18.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. On average, analysts anticipate that DBV Technologies S.A. will post -2.05 EPS for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.